SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
HealthDay News — Newer antianginal drugs (AA medications) such as ranolazine show substantial outcome improvements in chronic stable angina pectoris (CSA) compared to traditional medications, ...
Ranolazine is a novel antianginal agent that has also been shown to have electrophysiological properties in laboratory models. This is the first clinical evaluation of the antiarrythmic effects of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback